Nikhil Kamath's Latest Play: Investing $2.7 Million to Extend Lifespans. Is He Buying Time, or Just a Longer ROI?
Nikhil Kamath, ever the astute investor, seems to be literally buying time with his $2.7 million plunge into longevity startup Biopeak. While the rest of us are busy budgeting for retirement, Kamath appears to be budgeting for a post-retirement that lasts, well, indefinitely. One can't help but wonder if this is an altruistic play for societal health, or just a shrewd calculation that more life means more compound interest, more deals, and potentially, more time to avoid inheritance tax.
Founded in 2025 by Rishi Pardal and Shiva Subramanian, Biopeak positions itself as India's pioneering specialized brand dedicated to extending human lifespans through rigorous preventive care. Having opened its first clinic in Bengaluru last year, the company is already laying groundwork for expansion, with plans to launch a second facility in the bustling city within the coming month. This strategic growth, coupled with Kamath's significant backing, signals a burgeoning interest in making longevity accessible, at least for those who can afford early adoption of such futuristic health solutions.
